Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia gravis.

D M Linton1, D Philcox

  • 1Department of Anaesthetics, Groote Schuur Hospital, Cape Town, South Africa.

Disease-A-Month : DM
|November 1, 1990
PubMed
Summary
This summary is machine-generated.

Myasthenia Gravis is an autoimmune disorder causing muscle weakness by destroying acetylcholine receptors. Early diagnosis and treatment, including medications and immunotherapy, can lead to remission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of Vitamin B12 in the critically ill--a review.

Anaesthesia and intensive care·2016
Same author

Leptin levels and clinical outcomes in patients with systemic inflammatory response syndrome.

Anaesthesia and intensive care·2015
Same author

"HAIR" - a useful mnemonic.

Anaesthesia and intensive care·2012
Same author

Increased Vitamin B12 levels are associated with mortality in critically ill medical patients.

Clinical nutrition (Edinburgh, Scotland)·2011
Same author

Haemodynamic effects of negative pressure ventilation.

British journal of anaesthesia·2011
Same author

"Nature"--a useful mnemonic.

Anaesthesia and intensive care·2008
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology

Background:

  • Myasthenia Gravis (MG) is a neuromuscular disorder characterized by fluctuating muscle weakness.
  • It stems from an autoimmune attack targeting acetylcholine receptors, crucial for nerve-muscle communication.

Purpose of the Study:

  • To elucidate the complex nature of Myasthenia Gravis.
  • To emphasize the importance of understanding its immunological basis for effective patient management.

Main Methods:

  • Review of the natural history and immunological underpinnings of Myasthenia Gravis.
  • Discussion of current therapeutic strategies.

Main Results:

  • Variable muscle weakness, worsened by activity, is a key clinical feature.
  • Acetylcholinesterase inhibitors offer symptomatic relief.

Related Experiment Videos

  • Immunomodulatory treatments aim for long-term disease control.

    • Conclusions:

    • Optimal management of Myasthenia Gravis requires a comprehensive understanding of its pathophysiology.
    • Treatment strategies, including thymectomy and immunosuppressants, target the underlying immune imbalance.
    • Early intervention can lead to reversible disability and potentially permanent remission.